Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration

ASAIO Journal

Volumn 51, Issue 4, 2005, Pages 348-351

  Lavaud, Sylvie ^a   Paris, Bruno ^a   Maheut, Herve ^a   Randoux, Christine ^a   Renaux, Jean Louis ^a   Rieu, Philippe ^a   Chanard, Jacques ^a  

^a REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCOMPATIBILITY; DIALYSIS; HEALTH RISKS; HEMODYNAMICS; POLYACRYLONITRILES; POLYMERIC MEMBRANES;

HEMOCOMPATIBILITY; HEMODYALISIS; HEPARIN; POLYACRYLONITRILE MEMBRANES;

DIALYSIS MEMBRANES;

HEPARIN; POLYANION; POLYETHYLENEIMINE; SODIUM CHLORIDE;

ANTICOAGULATION; ARTICLE; BIOCOMPATIBILITY; BLEEDING; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIALYSIS MEMBRANE; DRUG BINDING; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; SURFACE CHARGE;

ACRYLIC RESINS; ANTICOAGULANTS; BIOCOMPATIBLE MATERIALS; BLOOD COAGULATION; CROSS-OVER STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XA; HEPARIN; HUMANS; MEMBRANES, ARTIFICIAL; PARTIAL THROMBOPLASTIN TIME; PILOT PROJECTS; POLYETHYLENEIMINE; PROSPECTIVE STUDIES; RENAL DIALYSIS; THROMBIN; TIME FACTORS;

EID: 23044433339     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mat.0000169121.09075.53     Document Type: Article

References (13)

1. Chanard J, Lavaud S, Randoux C, Rieu P: New insights in dialysis membrane biocompatibility: Relevance of adsorption properties and heparin binding. Nephrol Dial Transplant 18: 252-257, 2003.
2. Chanard J, Lavaud S, Touré F, Renaux JL, Crost T, Thomas M: Assessment of heparin binding to the AN69 ST hemodialysis membrane: I-Preclinical studies. ASAIO J 51: XXX-XXX, 2005.
3. Lavaud S, Canivet E, Wuillai A, et al: Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane. Nephrol Dial Transplant 18: 2097-2104, 2003.
4. Webb AR, Mythen MC, Jacobson D, Mackie IJ: Maintaining blood flow with extracorporeal circuit: Haemostasis and anticoagulation. Intensive Care Med 21: 84-93, 1995.
5. Arnadottir M, Kurkus J, Nilsson-Ehle P: Different types of heparin in haemodialysis: Long-term effects on post-heparin lipases. Scand J Clin Lab Invest 54: 515-521, 1994.
6. Massy ZA, Nguyen Khoa T, Lacour B et al: Dyslipidemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant 14: 2392-2397, 1999.
7. Leitienne P, Fouque D, Rigal D, Adeleine P, Trzeciak MC, Laville M: Heparin and blood polymorphonuclear stimulation in haemodialysis: an expansion of the biocompatibility concept. Nephrol Dial Transplant 15: 1631-1637, 2000.
8. Muriithi EW, Belcher PR, Day SP, Chaudkry M, Caslake MJ, Wheatley DJ: Lipolysis generates platelet dysfunction after in vivo heparin administration. Clin Sci 103: 433-440, 2002.
9. Mathur S, Devaroy S, Jialal I: Accelerated atherosclerosis, dyslipidemia and oxidative stress in end-stage renal disease. Curr Opin Nephrol Hypertens 11: 141-147, 2002.
10. Petitclerc T, Béné B, Jacobs C, Jandon MC, Coux N: Non invasive monitoring of effective dialysis dose delivered to the haemodialysis patient. Nephrol Dial Transplant 10: 212-216, 1995.
11. Thomas M, Valette P, Mausset AL, Dejardin P: High molecular weight kininogen adsorption on haemodialysis membranes: influence of pH and relationship with contact phase activation of blood plasma-influence of pre-treatment with poly (ethyle-imine). Int J Artif Organs 23: 20-26, 2000.
12. Mujais SK, Chimeh H: Heparin free hemodialysis using heparin coated hemophan. ASAIO J 42: 538-541, 1996.
13. Wynckel A, Cornillet J, Béné B, Stoltz A, Lepure C, Paris B, Chanard J: Improved removal of small proteins using continuous venovenous hemofiltration to treat acute renal failure. ASAIO J 50: 81-84, 2004.